Search research articles
Contact Us
Filters
Showing results (11-20 of 49) with videos related to
Page
of 5
Sort By:
Brain Research
|
April 6, 2004
Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence
Eva de Lago, Rosario de Miguel, Isabel Lastres-Becker, et al.
Molecular Neurobiology
|
October 24, 2007
Cannabinoids and neuroprotection in basal ganglia disorders
Onintza Sagredo, Moisés García-Arencibia, Eva de Lago, et al.
Neuroscience Letters
|
December 31, 2011
Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: relevance for in vitro studies with cannabinoids in motor neuron diseases
Miguel Moreno-Martet, Leyre Mestre, Frida Loría, et al.
Biomolecules
|
February 15, 2020
Pharmacokinetics of Sativex® in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders
María Fernández-Trapero, Carmen Pérez-Díaz, Francisco Espejo-Porras, et al.
Life Sciences
|
December 19, 2006
Neurochemical effects of the endocannabinoid uptake inhibitor UCM707 in various rat brain regions
Eva de Lago, Silvia Ortega-Gutiérrez, José A Ramos, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
June 28, 2025
Preclinical evaluation of cannabidiolic acid as a neuroprotective agent in TDP-43 transgenic mice, an experimental model of amyotrophic lateral sclerosis
Laura García-Toscano, Carmen Rodríguez-Cueto, Anna Furiano, et al.
Brain Research
|
January 2, 2007
Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties
Moisés García-Arencibia, Sara González, Eva de Lago, et al.
Biochemical Pharmacology
|
June 21, 2005
Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels
Eva de Lago, Stefania Petrosino, Marta Valenti, et al.
European Journal of Pharmacology
|
August 7, 2002
UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide
Eva de Lago, Javier Fernández-Ruiz, Silvia Ortega-Gutiérrez, et al.
British Journal of Pharmacology
|
March 26, 2018
Targeting glial cannabinoid CB<sub>2</sub> receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis
Francisco Espejo-Porras, Laura García-Toscano, Carmen Rodríguez-Cueto, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 49) with videos related to
Sort By:
Page
of 5
Brain Research
|
April 6, 2004
Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence
Eva de Lago, Rosario de Miguel, Isabel Lastres-Becker, et al.
Molecular Neurobiology
|
October 24, 2007
Cannabinoids and neuroprotection in basal ganglia disorders
Onintza Sagredo, Moisés García-Arencibia, Eva de Lago, et al.
Neuroscience Letters
|
December 31, 2011
Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: relevance for in vitro studies with cannabinoids in motor neuron diseases
Miguel Moreno-Martet, Leyre Mestre, Frida Loría, et al.
Biomolecules
|
February 15, 2020
Pharmacokinetics of Sativex® in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders
María Fernández-Trapero, Carmen Pérez-Díaz, Francisco Espejo-Porras, et al.
Life Sciences
|
December 19, 2006
Neurochemical effects of the endocannabinoid uptake inhibitor UCM707 in various rat brain regions
Eva de Lago, Silvia Ortega-Gutiérrez, José A Ramos, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
June 28, 2025
Preclinical evaluation of cannabidiolic acid as a neuroprotective agent in TDP-43 transgenic mice, an experimental model of amyotrophic lateral sclerosis
Laura García-Toscano, Carmen Rodríguez-Cueto, Anna Furiano, et al.
Brain Research
|
January 2, 2007
Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties
Moisés García-Arencibia, Sara González, Eva de Lago, et al.
Biochemical Pharmacology
|
June 21, 2005
Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels
Eva de Lago, Stefania Petrosino, Marta Valenti, et al.
European Journal of Pharmacology
|
August 7, 2002
UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide
Eva de Lago, Javier Fernández-Ruiz, Silvia Ortega-Gutiérrez, et al.
British Journal of Pharmacology
|
March 26, 2018
Targeting glial cannabinoid CB<sub>2</sub> receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis
Francisco Espejo-Porras, Laura García-Toscano, Carmen Rodríguez-Cueto, et al.
Page
of 5